Home Cart Sign in  
Chemical Structure| 156-54-7 Chemical Structure| 156-54-7

Structure of Sodium Butyrate
CAS No.: 156-54-7

Chemical Structure| 156-54-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Sodium Butyrate is a HDAC inhibitor that induces cell differentiation and inhibits cell proliferation. Sodium Butyrate can be used in research on cancer, inflammatory diseases, and metabolic disorders.

Synonyms: Butyric Acid; NaB; Butanoic acid sodium salt

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Binienda, Agata ; Machelak, Weronika ; Zielińska, Marta ; Fichna, Jakub ;

Abstract: High incidence of colorectal cancer (CRC) is influenced by diet low in fiber (source of short chain fatty acids, SCFAs, natural agonists for free fatty acid receptor type 2 (FFAR2)) and high in fat (main source of long chain fatty acids, LCFAs, FFAR4 agonists). FFAR2 and FFAR4 are downregulated in CRC. In this study, we characterized whether the anticancer effects of SCFAs and LCFAs are FFAR-dependent in in vitro and in vivo models of CRC. In vitro, SW-480 cell growth was determined after incubation with FFARs ligands (SCFAs: acetate, butyrate; LCFAs: palmitate, stearate) using MTT assay. Cell migration and invasion were investigated by wound healing and transwell-based invasion assays. In vivo, SCFAs and LCFAs were administered to azoxymethane/dextran sodium sulfate-treated mice. Real-time qPCR and Western blot were used to determine FFARs expression. SCFAs and LCFAs significantly decreased SW-480 cell growth, migration and invasion capacities. Combination of SCFAs and LCFAs induced synergistic inhibitory effects on CRC cell growth and motility. FFAR2 and FFAR4 expression were elevated in CRC cells treated with butyrate as well as with butyrate+acetate, and butyrate+palmitate+stearate. Concurrently, only FFAR4 expression was increased in CRC cells incubated with LCFAs. In vivo, treatment with LCFAs, but not SCFAs increased ffar2 and Ffar4 expression. Our findings showed that SCFAs and LCFAs inhibit cancer cell growth and their migration and invasion capabilities. Our study evidenced that the anticancer effects of SCFAs- and LCFAs are mediated by FFAR2 and FFAR4.

Purchased from AmBeed:

Alternative Products

Product Details of Sodium Butyrate

CAS No. :156-54-7
Formula : C4H7NaO2
M.W : 110.09
SMILES Code : CCCC([O-])=O.[Na+]
Synonyms :
Butyric Acid; NaB; Butanoic acid sodium salt
MDL No. :MFCD00002816
InChI Key :MFBOGIVSZKQAPD-UHFFFAOYSA-M
Pubchem ID :5222465

Safety of Sodium Butyrate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Sodium Butyrate

epigenetics

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01862380 Adrenal Hyperplasia, Congenita... More >>l 21-hydroxylase Deficiency Less << Not Applicable Unknown November 2016 France ... More >> Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital Le Kremlin-bicetre, France, 94 275 Less <<
NCT03401398 Septic Shock Phase 3 Not yet recruiting April 30, 2023 -
NCT03110198 Ulcerative Colitis, Unspecifie... More >>d Less << Phase 4 Recruiting March 2018 China, Shaanxi ... More >> Xijing Digestive Disease Recruiting Xi'an, Shaanxi, China, 710032 Contact: Jie liang, professor    86-029-84771535    liangjie@fmmu.edu.cn Less <<
NCT03766997 Granulomatous Mastitis Phase 4 Not yet recruiting January 2022 China, Beijing ... More >> Department of Breast Surgery,Peking Union Medical College Hospital Beijing, Beijing, China, 100730 Less <<
NCT01797562 Allergic Contact Dermatitis Phase 4 Unknown December 2015 United States, California ... More >> Rady Children's Hospital Recruiting San Diego, California, United States, 92123 Contact: Ann Funk, RN    858-576-1700 ext 4295       Principal Investigator: Lawrence Eichenfield, MD          United States, Colorado Anschutz Health and Wellness Center, University of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Teresa Derian, RN    303-724-9155       Principal Investigator: Cory Dunnick, MD          United States, Kentucky Dermatology Specialists Recruiting Louisville, Kentucky, United States, 40202 Contact: Maureen Beyel, RN    502-582-7546       Principal Investigator: Joseph Fowler, MD          United States, Oregon Oregon Health & Science University Recruiting Portland, Oregon, United States, 97239 Contact: Kristin Morton    503-494-6442       Principal Investigator: Patricia Norris, MD Less <<
NCT01518348 Contact Dermatitis Phase 3 Withdrawn(Study has been updat... More >>ed with new protocol number) Less << December 2013 United States, Colorado ... More >> Anschutz Health and Wellness Center, University of Colorado Aurora, Colorado, United States, 80045 United States, Kentucky Dermatology Specialists Louisville, Kentucky, United States, 40202 Less <<
NCT00640614 Contact Dermatitis Phase 3 Completed - United States, Arkansas ... More >> River City Dermatology Little Rock, Arkansas, United States, 72205 United States, Kansas American Dermatology Associates Shawnee, Kansas, United States, 66216 United States, Kentucky Dermatology Specialists PSC Louisville, Kentucky, United States, 40202-1864 United States, New York Winthrop University Hospital Mineola, New York, United States, 11501 Denmark Odense University Hospital Odense C, Denmark, DK-5000 Less <<
NCT02090504 Alcohol Withdrawal Syndrome ... More >> Alcohol Dependence Less << Phase 4 Completed - Austria ... More >> University of Wien Wien, AT, Austria Italy "G. Fontana" Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Clinical Medicine, University of Bologna Bologna, BO, Italy Catholic University of Rome Rome, Rm, Italy, 00168 Less <<
NCT00672308 Cholera Phase 2 Completed - Bangladesh ... More >> ICDDR,B Dhaka, Bangladesh, 1212 Less <<
NCT01757379 Short Chain Fatty Acids Bioava... More >>ilability Less << Not Applicable Completed - Belgium ... More >> KU Leuven/ UZ Leuven Leuven, Vlaams-Brabant, Belgium, 3000 Less <<
NCT01983046 Obesity Type ... More >>2 Diabetes Less << Not Applicable Completed - Netherlands ... More >> University Maastricht Maastricht, Limburg, Netherlands, 6229 ER Less <<
NCT00843167 Breast Cancer ... More >> Precancerous Condition Less << Phase 2 Completed - United States, Oregon ... More >> Knight Cancer Institute at Oregon Health and Science University Portland, Oregon, United States, 97239-3098 Less <<
NCT00843167 - Completed - -
NCT00693355 Healthy Not Applicable Completed - Netherlands ... More >> University of Maastricht Maastricht, Limburg, Netherlands, 6202MD Less <<
NCT00640614 - Completed - -
NCT00800930 Shigellosis Phase 2 Completed - Bangladesh ... More >> Dhaka Hospital & Matlab Hospital Dhaka, Bangladesh, 1212 ICDDR,B Dhaka, Bangladesh, 1212 Less <<
NCT03010865 Schizophrenic Disorder ... More >> Cognitive Impairment Less << Phase 2 Phase 3 Not yet recruiting February 2020 China, Shanghai ... More >> Shanghai Mental Health Center Not yet recruiting Shanghai, Shanghai, China, 200030 Contact: Chunbo Li, M.D.    86-21-34773243    chunbo_li@163.com    Principal Investigator: Chunbo Li, M.D. Less <<
NCT02654405 Schizophrenic Disorders ... More >> Cognitive Function Less << Phase 2 Phase 3 Withdrawn(Nathan Kline Institu... More >>te (NKI) decided not to accept study grant from Stanley Medical Research Foundation. because of budget considerations.) Less << May 2016 United States, New York ... More >> Nathan Kline Insitute for Psychiatric Research Orangeburg,, New York, United States, 10962 Less <<
NCT00696098 Gut Health Not Applicable Completed - Netherlands ... More >> University of Maastricht Maastricht, Limburg, Netherlands, 6202 MD Less <<
NCT02271802 SCFA Metabolism Not Applicable Completed - Netherlands ... More >> Maastricht University Maastricht, Netherlands, 6229ER Less <<
NCT05576597 Rheumatoid Arthritis PHASE2 COMPLETED 2024-06-15 Department of Rheumatology and... More >> Immunology, Peking University People's Hospital, Beijing, Beijing, 100044, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

9.08mL

1.82mL

0.91mL

45.42mL

9.08mL

4.54mL

90.83mL

18.17mL

9.08mL

References

 

Historical Records

Categories